106 related articles for article (PubMed ID: 2144165)
21. Relative cytotoxicities of adriamycin and epirubicin in combination with lonidamine against human bladder cancer cell lines.
Popert RJ; Masters JR; Coptcoat M; Zupi G
Urol Res; 1995; 22(6):367-72. PubMed ID: 7740656
[TBL] [Abstract][Full Text] [Related]
22. Augmentation of cisplatin sensitivity in cisplatin-resistant human bladder cancer cells by modulating glutathione concentrations and glutathione-related enzyme activities.
Byun SS; Kim SW; Choi H; Lee C; Lee E
BJU Int; 2005 May; 95(7):1086-90. PubMed ID: 15839938
[TBL] [Abstract][Full Text] [Related]
23. Characterization of chemoresistance mechanisms in a series of cisplatin-resistant transitional carcinoma cell lines.
Hour TC; Chen J; Huang CY; Guan JY; Lu SH; Hsieh CY; Pu YS
Anticancer Res; 2000; 20(5A):3221-5. PubMed ID: 11062746
[TBL] [Abstract][Full Text] [Related]
24. Cytostatic sensitivity and MDR in bladder carcinoma cells: implications for tumor therapy.
Schuldes H; Dolderer JH; Schoch C; Bickeböller R; Woodcock BG
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):204-8. PubMed ID: 10783830
[TBL] [Abstract][Full Text] [Related]
25. Genetic basis of drug sensitivity in human testis tumour cells.
Wang X; Hafezparast M; Masters JR
Int J Cancer; 1996 Feb; 65(4):426-31. PubMed ID: 8621221
[TBL] [Abstract][Full Text] [Related]
26. The relative activity of cisplatin, oxaliplatin and satraplatin in testicular germ cell tumour sensitive and resistant cell lines.
Perry J; Powles T; Shamash J; Veerupillai A; McGrowder E; Noel E; Lu YJ; Oliver T; Joel S
Cancer Chemother Pharmacol; 2009 Oct; 64(5):925-33. PubMed ID: 19263053
[TBL] [Abstract][Full Text] [Related]
27. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
28. Deficient repair of cisplatin-DNA adducts identified in human testicular teratoma cell lines established from tumours from untreated patients.
Hill BT; Scanlon KJ; Hansson J; Harstrick A; Pera M; Fichtinger-Schepman AM; Shellard SA
Eur J Cancer; 1994; 30A(6):832-7. PubMed ID: 7917544
[TBL] [Abstract][Full Text] [Related]
29. Establishment and characterization of a doxorubicin-resistant human bladder cancer cell line (MGH-U1R).
McGovern F; Kachel T; Vijan S; Schiff S; Lin CW; Prout GR
J Urol; 1988 Aug; 140(2):410-4. PubMed ID: 3398164
[TBL] [Abstract][Full Text] [Related]
30. Cytotoxicity of arsenic trioxide to transitional carcinoma cells.
Pu YS; Hour TC; Chen J; Huang CY; Guan JY; Lu SH
Urology; 2002 Aug; 60(2):346-50. PubMed ID: 12137851
[TBL] [Abstract][Full Text] [Related]
31. Ras oncogene point mutations in bladder cancer resistant to cisplatin.
Wood DP; Anderson AE; Fair R; Chaganti RS
Urol Res; 1992; 20(4):313-6. PubMed ID: 1509639
[TBL] [Abstract][Full Text] [Related]
32. Distinct mechanisms contribute to acquired cisplatin resistance of urothelial carcinoma cells.
Höhn A; Krüger K; Skowron MA; Bormann S; Schumacher L; Schulz WA; Hoffmann MJ; Niegisch G; Fritz G
Oncotarget; 2016 Jul; 7(27):41320-41335. PubMed ID: 27191498
[TBL] [Abstract][Full Text] [Related]
33. Dipyridamole-cisplatin potentiation: enhanced in vivo cytotoxicity in xenograft models of human testicular and bladder cancers.
Keane TE; Rosner G; Donaldson JT; Norwood DL; Poulton SH; Walther PJ
J Urol; 1990 Oct; 144(4):1004-9. PubMed ID: 2398547
[TBL] [Abstract][Full Text] [Related]
34. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
35. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide.
Mizutani Y; Fukumoto M; Bonavida B; Yoshida O
Cancer; 1994 Nov; 74(9):2546-54. PubMed ID: 7923012
[TBL] [Abstract][Full Text] [Related]
37. Establishment and characterization of doxorubicin-resistant human bladder cancer cell line, KK47/ADM.
Kimiya K; Naito S; Soejima T; Sakamoto N; Kotoh S; Kumazawa J; Tsuruo T
J Urol; 1992 Aug; 148(2 Pt 1):441-5. PubMed ID: 1353119
[TBL] [Abstract][Full Text] [Related]
38. DNA repair capacity and cisplatin sensitivity of human testis tumour cells.
Köberle B; Grimaldi KA; Sunters A; Hartley JA; Kelland LR; Masters JR
Int J Cancer; 1997 Mar; 70(5):551-5. PubMed ID: 9052754
[TBL] [Abstract][Full Text] [Related]
39. Factors influencing the sensitivity of two human bladder carcinoma cell lines to cis-diamminedichloroplatinum(II).
Bedford P; Walker MC; Sharma HL; Perera A; McAuliffe CA; Masters JR; Hill BT
Chem Biol Interact; 1987 Jan; 61(1):1-15. PubMed ID: 3815585
[TBL] [Abstract][Full Text] [Related]
40. Titanocendichloride activity in cisplatin and doxorubicin-resistant human ovarian carcinoma cell lines.
Harstrick A; Schmoll HJ; Sass G; Poliwoda H; Rustum Y
Eur J Cancer; 1993; 29A(7):1000-2. PubMed ID: 8499130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
